Home Slide
EvoRx Technologies | innovative peptide therapeutic and targeted radiopharmaceuticals
EvoRx strives to discover and develop innovative peptide therapeutic and targeted radiopharmaceuticals for treatment and diagnosis of disease with high unmet medical need. It’s proprietary Evo-Link™ technology rapidly generates exceedingly high diversity cyclic peptide libraries. The libraries are screened for drug-like activity in environments that mimic the physiological environment of the body. This results in EvoTides™, uniquely structured peptides that are highly stable in human serum, have antibody-like specificity and affinity, and can be designed to be membrane permeable. These features allow us to target protein interactions previously thought of as “undruggable.”
peptide therapy radiopharmaceuticals protein interaction cyclic peptide libraries
2314
home,page,page-id-2314,page-template-default,ajax_fade,page_not_loaded,

 
 
EvoRx strives to discover and develop innovative peptide therapeutic and targeted radiopharmaceuticals for treatment and diagnosis of disease with high unmet medical need. It’s proprietary Evo-Link™ technology rapidly generates exceedingly high diversity cyclic peptide libraries. The libraries are screened for drug-like activity in environments that mimic the physiological environment of the body. This results in EvoTides™, uniquely structured peptides that are highly stable in human serum, have antibody-like specificity and affinity, and can be designed to be membrane permeable. These features allow us to target protein interactions previously thought of as “undruggable.”